Business, energy, technology, markets and global industry news from Business News Today

addiction medicine

PharmaDeviceNews addiction medicine
Representative image of a clinician preparing an injectable treatment in an outpatient care setting, illustrating Braeburn’s latest BRIXADI data on long-acting buprenorphine, opioid withdrawal suppression, and treatment retention in opioid use disorder.
Pharma & Biotech

Braeburn’s BRIXADI evidence package raises new questions for injectable buprenorphine adoption

Braeburn’s new BRIXADI data shows retention and dosing signals in opioid use disorder. Find out what it means for treatment strategy.

Read More
Pharma & Biotech

How Clearmind Medicine is positioning CMND-100 within the emerging non-hallucinogenic neuroplastogen market

Clearmind Medicine is advancing CMND-100 in Alcohol Use Disorder. Discover why the non-hallucinogenic neuroplastogen market is gaining attention.

Read More
AltaPointe ketamine protocol may change how buprenorphine is started in fentanyl dependence
Pharma & Biotech

Why AltaPointe’s ketamine-assisted protocol could reshape opioid withdrawal management

Find out how a low-dose ketamine protocol may help fentanyl users start buprenorphine faster and with less withdrawal discomfort.

Read More